Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients

Abstract Purpose The purpose of the current study was to compare the postoperative complications, overall survival and disease-free survival in young and old gastric cancer patients after gastrectomy using propensity score matching (PSM). Methods Adult patients (aged ≥ 18 years) who underwent gastrectomy for gastric cancer in a single clinical center from January 2013 to December 2017 were enrolled continuously for retrospective analysis. To minimize the selection bias between the young and old groups, the PSM was conducted in this study. Results A total of 558 patients were included in this study, with 51 patients in the young group (aged ≤ 45 years) and 507 patients in the old group (aged > 45 years). After 1:1 matching according to PSM, 51 patients in the young group were matched to 51 patients in the old group. After PSM, there was no difference in the baseline information. In terms of short-term outcomes, no difference was found in operation time (P = 0.190), intraoperative blood loss (P = 0.336), retrieved lymph nodes (P = 0.948), blood transfusion (P = 0.339), postoperative hospital stay (P = 0.194), or postoperative complications (P = 0.477) between the two groups. For overall survival, no statistically significant difference was found in all stages (P = 0.383), stage I (P = 0.431), stage II (P = 0.875) or stage III (P = 0.446) gastric cancer. Furthermore, regarding disease-free survival, no differences were found between the two groups in all stages (P = 0.378), stage I (P = 0.431), stage II (P = 0.879) or stage III (P = 0.510) gastric cancer. Conclusion Age might not be an independent prognostic factor for short-term outcomes, OS, or DFS in gastric cancer patients who underwent gastrectomy. The pTNM stage of GC might be an independent prognostic factor for OS and DFS.

Download Full-text

HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy

PLoS ONE ◽

10.1371/journal.pone.0090678 ◽

2014 ◽

Vol 9 (3) ◽

pp. e90678 ◽

Cited By ~ 26

Author(s):

Li Chen ◽

Yan Shi ◽

Jing Yuan ◽

Yalin Han ◽

Rui Qin ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Disease Free Survival ◽

Poor Overall Survival ◽

Free Survival ◽

Gastric Cancer Patients ◽

Disease Free

Download Full-text

501 POSTER Expression of microRNA-451 is associated with disease-free survival in gastric cancer patients treated with chemoradiotherapy after gastric resection

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70440-8 ◽

2007 ◽

Vol 5 (4) ◽

pp. 90

Author(s):

E. Bandres ◽

N. Bitarte ◽

F. Arias ◽

R. Zarate ◽

X. Agirre ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Gastric Resection ◽

Disease Free Survival ◽

Free Survival ◽

Gastric Cancer Patients ◽

Disease Free

Download Full-text

Preoperative Anemia or Low Hemoglobin Predicts Poor Prognosis in Gastric Cancer Patients: A Meta-Analysis

Disease Markers ◽

10.1155/2019/7606128 ◽

2019 ◽

Vol 2019 ◽

pp. 1-9 ◽

Cited By ~ 3

Author(s):

Xuan-zhang Huang ◽

Yu-chong Yang ◽

You Chen ◽

Cong-cong Wu ◽

Rui-fang Lin ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Poor Prognosis ◽

Prognostic Value ◽

Disease Free Survival ◽

Preoperative Anemia ◽

Free Survival ◽

Effect Model ◽

Gastric Cancer Patients ◽

Disease Free

Background. The prognostic value of preoperative anemia in gastric cancer remains unclear. Therefore, the purpose of the present study is to evaluate the prognostic value of preoperative anemia in gastric cancer. Methods. We searched Embase and PubMed databases for relevant studies from inception to March 2018. The prognostic value of preoperative anemia in gastric cancer was determined by calculating the hazard ratio (HR) and the corresponding 95% confidence interval (CI) as effect measures. A random effect model was used in cases in which there was significant heterogeneity; otherwise, a fixed effect model was used. Statistical analyses were performed using Stata software. Results. Seventeen studies involving 13,154 gastric cancer patients were included. The estimated rate of preoperative anemia was 36% (95%CI=27-44%). The overall survival of preoperative anemia was poor (HR=1.33, 95%CI=1.21-1.45). Moreover, disease-free survival was significantly lower in patients with preoperative anemia compared with those without this condition (HR=1.62, 95%CI=1.13-2.32). These findings were corroborated by the results of subgroup analyses. Conclusions. The results indicate that preoperative anemia predicts poor prognosis in gastric cancer, including overall survival and disease-free survival. Therefore, preoperative anemia may be a convenient and cost-effective blood-derived prognostic marker for gastric cancer.

Download Full-text

Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy

Virchows Archiv ◽

10.1007/s00428-020-02878-6 ◽

2020 ◽

Author(s):

Dan Jiang ◽

Chang Shu ◽

Weihan Zhang ◽

Linyong Sun ◽

Mengni Zhang ◽

...

Keyword(s):

Gastric Cancer ◽

Neoadjuvant Chemotherapy ◽

Microsatellite Instability ◽

Cancer Patients ◽

Disease Free Survival ◽

Free Survival ◽

Low Level ◽

Gastric Cancer Patients ◽

Disease Free ◽

Short Disease Free Survival

Download Full-text

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer

Integrative Cancer Therapies ◽

10.1177/1534735417753542 ◽

2018 ◽

Vol 17 (3) ◽

pp. 619-627 ◽

Cited By ~ 5

Author(s):

Yu Kyung Lee ◽

Kyeore Bae ◽

Hwa-Seung Yoo ◽

Seung-Hun Cho

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Survival Rate ◽

Survival Data ◽

Disease Free Survival ◽

Free Survival ◽

Traditional Medicines ◽

Resectable Gastric Cancer ◽

Gastric Cancer Patients ◽

Disease Free

Introduction: Stomach cancer, historically, has a low survival rate advances in curative resection procedures. Objectives: To assess the potential benefits of traditional herbal medicines in conjunction with chemotherapy in postoperative gastric cancer patients in terms of overall survival and disease-free survival. Data Sources: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, a Chinese database (CNKI), a Korean database, a Japanese database, AMED, and CINAHL up to September 2016. We summarized survival data from all RCTs. Study Selection: All RCTs of oral traditional medicines for resectable gastric cancer compared with chemotherapy alone were eligible. Data Extraction: Thirteen eligible trials with survival data (1075 patients) were deemed eligible for inclusion. Results: There were 217 documented deaths of the 574 patients assigned to adjuvant traditional medicines groups and 319 documented deaths of the 501 patients assigned to the chemotherapy-only groups. Adjuvant traditional medicines were associated with a statistically significant benefit in terms of overall survival rate (hazard ratio = 0.56; 95% confidence interval = 0.47-0.66; P < .00001) and disease-free survival (hazard ratio = 0.54; 95% confidence interval = 0.43-0.66; P < .00001). Conclusion: Among the RCTs included, the inclusion of postoperative adjuvant traditional medicines was associated with reduced risk of death in gastric cancer patients, when survival rates were compared with the group of patients who received chemotherapy alone. However, most of the included studies utilized are thought to be of low quality, so it would certainly appear that more trials are both advisable and necessary to arrive at correct and convincing conclusions.

Download Full-text